A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Skin Diseases, Infectious
Intervention: Levofloxacin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an
antibiotic, compared with another antibiotic, ciprofloxacin, in the treatment of adults with
uncomplicated infections of the skin and the supportive layers beneath the skin.
Clinical Details
Official title: A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Ciprofloxacin HCl in the Treatment of Uncomplicated Skin and Skin Structure Infections in Adults
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Clinical response rate at post-therapy (defined as cured, improved or failed); microbiological response at post-therapy (rate of elimination of disease-causing bacteria, by patient, and by type of bacteria); incidence of adverse events
Secondary outcome: Changes in physical examination and laboratory tests after treatment with the study drug
Detailed description:
Levofloxacin is an antibacterial agent used for the treatment of many types of infections in
adults. This is a randomized, double-blind, parallel group, multicenter study to determine
the safety and effectiveness of levofloxacin (500 mg once daily for 7 days) compared with
ciprofloxacin (500 mg once every 12 hours for 10 days) in adults with uncomplicated
infections of the skin and the supportive layers beneath the skin. The study consists of 3
visits: one visit for screening and enrollment, and 2 visits for assessment of safety and
effectiveness (one visit on Days 3 - 5 of the study and one visit [post-therapy] 2 - 7 days
after the last dose of the study drug). The total duration of patient participation in the
study is approximately 2 weeks. The primary assessments of effectiveness include the
clinical response to treatment (categorized at post-therapy as cured, improved, or failed)
and the microbiological response at post-therapy (the elimination of the disease-causing
bacteria, categorized as eradicated, partially eradication, or persisted, determined by
patient and by type of bacteria). Safety evaluations (incidence of adverse events, physical
examination, and laboratory tests) are performed throughout the study. The study hypothesis
is that treatment with levofloxacin is at least as effective and as well tolerated as
treatment with ciprofloxacin in patients with uncomplicated infections of the skin and the
supportive layers beneath the skin. One levofloxacin 500 mg tablet by mouth, once daily
(and a placebo tablet once daily, 12 hours later) for 7 days, followed by one placebo tablet
every 12 hours for 3 days; or one ciprofloxacin 500 mg tablet by mouth once every 12 hours
for 10 days.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of infection of the skin and/or the supportive layers beneath the skin, as
indicated by pain at the site of the infection, redness, swelling, drainage, or other
relevant clinical signs
- able to provide a sample of tissue from the affected area of the skin
- able to receive oral medications.
Exclusion Criteria:
- Patients with a condition requiring treatment with antibiotics by injection into a
vein, a muscle, or beneath the skin
- having a severe infection
- previous allergic or serious adverse reaction to similar antibiotics, or have severe
lactose intolerance
- taken antibiotics internally within 48 hours of the start of the study with resulting
improvement
- requirement of a second antibiotic taken internally or requirement of an antibiotic
applied directly to the site of the infection in addition to the study drug
Locations and Contacts
Additional Information
A study of the safety and effectiveness of oral levofloxacin compared with oral ciprofloxacin in the treatment of adults with uncomplicated infections of the skin and the supportive layers beneath the skin
Starting date: January 1993
Last updated: June 8, 2011
|